Clinical Trials


This is an open label phase I dose-escalation study. Healthy male subjects receive a single dose of PG102 or multiple (3 weekly) doses of PG102 or placebo in a randomized fashion. The study design has been selected in order to collect safety, pharmacokinetic and pharmacodynamic data to support further development of PG102 across multiple indications. The study has been successfully completed.